Extracellular cyclophilin A may be a potential target to protect against myocardial reperfusion injury

Medical Hypotheses

Volumn 77, Issue 5, 2011, Pages 734-738

  Wang, W L ^a   Yuan, Y J ^a   Xue, F S ^a   Liao, X ^a   Wang, Q ^a   Xiong, J ^a   Liu, J H ^a  

^a PLASTIC SURGERY HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD147 ANTIGEN; CYCLOPHILIN A; CYCLOPHILIN INHIBITOR; GELATINASE B; I KAPPA B; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MM 218; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL COMMUNICATION; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

CYCLOPHILIN A; CYTOKINES; ENZYME INDUCTION; HUMANS; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASES; MODELS, THEORETICAL; MYOCARDIAL REPERFUSION INJURY;

EID: 80053976933     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.07.026     Document Type: Article

References (61)

1. Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003, 361(9351):13-20.
2. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 2007, 357(11):1121-1135.
3. Hausenloy D.J., Yellon D.M. Time to take myocardial reperfusion injury seriously. N Engl J Med 2008, 359(5):518-520.
4. Frangogiannis N.G. The role of the chemokines in myocardial ischemia and reperfusion. Curr Vasc Pharmacol 2004, 2(2):163-174.
5. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004, 61(3):481-497.
6. Handschumacher R.E., Harding M.W., Rice J., Drugge R.J., Speicher D.W. Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science 1984, 226(4674):544-547.
7. Arora K., Gwinn W.M., Bower M.A., Watson A., Okwumabua I., MacDonald H.R., et al. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol 2005, 175(1):517-522.
8. Gwinn W.M., Damsker J.M., Falahati R., Okwumabua I., Kelly-Welch A., Keegan A.D., et al. Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention. J Immunol 2006, 177(7):4870-4879.
9. Sherry B., Yarlett N., Strupp A., Cerami A. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci U S A 1992, 89(8):3511-3515.
10. Xu Q., Leiva M.C., Fischkoff S.A., Handschumacher R.E., Lyttle C.R. Leukocyte chemotactic activity of cyclophilin. J Biol Chem 1992, 267(17):11968-11971.
11. Damsker J.M., Bukrinsky M.I., Constant S.L. Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J Leukoc Biol 2007, 82(3):613-618.
12. Jin Z.G., Lungu A.O., Xie L., Wang M., Wong C., Berk B.C. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol 2004, 24(7):1186-1191.
13. Kim H., Kim W.J., Jeon S.T., Koh E.M., Cha H.S., Ahn K.S., et al. Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol 2005, 116(3):217-224.
14. Yuan W., Ge H., He B. Pro-inflammatory activities induced by CyPA-EMMPRIN interaction in monocytes. Atherosclerosis 2010, 213(2):415-421.
15. Yang Y., Lu N., Zhou J., Chen Z.N., Zhu P. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47(9):1299-1310.
16. Seizer P., Schonberger T., Schott M., Lang M.R., Langer H.F., Bigalke B., et al. EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. Atherosclerosis 2010, 209(1):51-57.
17. Yurchenko V., Constant S., Eisenmesser E., Bukrinsky M. Cyclophilin-CD147 interactions: A new target for anti-inflammatory therapeutics. Clin Exp Immunol 2010, 160(3):305-317.
18. Seko Y., Fujimura T., Taka H., Mineki R., Murayama K., Nagai R. Hypoxia followed by reoxygenation induces secretion of cyclophilin A from cultured rat cardiac myocytes. Biochem Biophys Res Commun 2004, 317(1):162-168.
19. Damsker J.M., Okwumabua I., Pushkarsky T., Arora K., Bukrinsky M.I., Constant S.L. Targeting the chemotactic function of CD147 reduces collagen-induced arthritis. Immunology 2009, 126(1):55-62.
20. Fischer G., Wittmann-Liebold B., Lang K., Kiefhaber T., Schmid F.X. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1989, 337(6206):476-478.
21. Takahashi N., Hayano T., Suzuki M. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989, 337(6206):473-475.
22. Malesevic M., Kuhling J., Erdmann F., Balsley M.A., Bukrinsky M.I., Constant S.L., et al. A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins. Angew Chem Int Ed Engl 2010, 49(1):213-215.
23. Balsley M.A., Malesevic M., Stemmy E.J., Gigley J., Jurjus R.A., Herzog D., et al. A cell-impermeable cyclosporine A derivative reduces pathology in a mouse model of allergic lung inflammation. J Immunol 2010, 185(12):7663-7670.
24. Jennings R.B., Sommers H.M., Smyth G.A., Flack H.A., Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960, 70:68-78.
25. Steffens S., Montecucco F., Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009, 102(2):240-247.
26. Entman M.L., Michael L., Rossen R.D., Dreyer W.J., Anderson D.C., Taylor A.A., et al. Inflammation in the course of early myocardial ischemia. FASEB J 1991, 5(11):2529-2537.
27. Sunnergren KP, Rovetto MJ. Myocyte and endothelial injury with ischemia reperfusion in isolated rat hearts. Am J Physiol 1987; 252(6 Pt 2): H1211-7.
28. Rezkalla S.H., Kloner R.A. No-reflow phenomenon. Circulation 2002, 105(5):656-662.
29. Boyle E.M., Kovacich J.C., Hebert C.A., Canty T.G., Chi E., Morgan E.N., et al. Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury. J Thorac Cardiovasc Surg 1998, 116(1):114-121.
30. Fischer G., Bang H., Mech C. Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides. Biomed Biochim Acta 1984, 43(10):1101-1111.
31. Galat A. Peptidylprolyl cis/trans isomerases (immunophilins): Biological diversity-targets-functions. Curr Top Med Chem 2003, 3(12):1315-1347.
32. Galat A. Peptidylproline cis-trans-isomerases: Immunophilins. Eur J Biochem 1993, 216(3):689-707.
33. Kim S.H., Lessner S.M., Sakurai Y., Galis Z.S. Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am J Pathol 2004, 164(5):1567-1574.
34. Tegeder I., Schumacher A., John S., Geiger H., Geisslinger G., Bang H., et al. Elevated serum cyclophilin levels in patients with severe sepsis. J Clin Immunol 1997, 17(5):380-386.
35. Billich A., Winkler G., Aschauer H., Rot A., Peichl P. Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J Exp Med 1997, 185(5):975-980.
36. Coppinger J.A., Cagney G., Toomey S., Kislinger T., Belton O., McRedmond J.P., et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004, 103(6):2096-2104.
37. Kim J.Y., Kim W.J., Kim H., Suk K., Lee W.H. The stimulation of CD147 induces MMP-9 expression through ERK and NF-κB in macrophages: Implication for atherosclerosis. Immune Netw 2009, 9(3):90-97.
38. Bukrinsky M.I. Cyclophilins: Unexpected messengers in intercellular communications. Trends Immunol 2002, 23(7):323-325.
39. Iacono K.T., Brown A.L., Greene M.I., Saouaf S.J. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol 2007, 83(3):283-295.
40. Yurchenko V., Zybarth G., O'Connor M., Dai W.W., Franchin G., Hao T., et al. Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem 2002, 277(25):22959-22965.
41. Schlegel J., Redzic J.S., Porter C.C., Yurchenko V., Bukrinsky M., Labeikovsky W., et al. Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A. J Mol Biol 2009, 391(3):518-535.
42. Hanoulle X., Melchior A., Sibille N., Parent B., Denys A., Wieruszeski J.M., et al. Structural and functional characterization of the interaction between cyclophilin B and a heparin-derived oligosaccharide. J Biol Chem 2007, 282(47):34148-34158.
43. Konttinen Y.T., Li T.F., Mandelin J., Liljestrom M., Sorsa T., Santavirta S., et al. Increased expression of extracellular matrix metalloproteinase inducer in rheumatoid synovium. Arthritis Rheum 2000, 43(2):275-280.
44. Satoh K., Nigro P., Matoba T., O'Dell M.R., Cui Z., Shi X., et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensinII-induced aortic aneurysms. Nat Med 2009, 15(6):649-656.
45. Satoh K., Matoba T., Suzuki J., O'Dell M.R., Nigro P., Cui Z., et al. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation 2008, 117(24):3088-3098.
46. Nigro P., Satoh K., O'Dell M.R., Soe N.N., Cui Z., Mohan A., et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2011, 208(1):53-66.
47. Satoh K., Shimokawa H., Berk B.C. Cyclophilin A: Promising new target in cardiovascular therapy. Circ J 2010, 74(11):2249-2256.
48. Satoh K., Nigro P., Berk B.C. Oxidative stress and vascular smooth muscle cell growth: A mechanistic linkage by cyclophilin A. Antioxid Redox Signal 2010, 12(5):675-682.
49. Spik G., Haendler B., Delmas O., Mariller C., Chamoux M., Maes P., et al. A novel secreted cyclophilin-like protein (SCYLP). J Biol Chem 1991, 266(17):10735-10738.
50. Allain F., Boutillon C., Mariller C., Spik G. Selective assay for CyPA and CyPB in human blood using highly specific anti-peptide antibodies. J Immunol Methods 1995, 178(1):113-120.
51. Yurchenko V., O'Connor M., Dai W.W., Guo H., Toole B., Sherry B., et al. CD147 is a signaling receptor for cyclophilin B. Biochem Biophys Res Commun 2001, 288(4):786-788.
52. Allain F., Vanpouille C., Carpentier M., Slomianny M.C., Durieux S., Spik G. Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix. Proc Natl Acad Sci U S A 2002, 99(5):2714-2719.
53. Melchior A., Denys A., Deligny A., Mazurier J., Allain F. Cyclophilin B induces integrin-mediated cell adhesion by a mechanism involving CD98-dependent activation of protein kinase C-delta and p44/42 mitogen-activated protein kinases. Exp Cell Res 2008, 314(3):616-628.
54. De Ceuninck F., Allain F., Caliez A., Spik G., Vanhoutte P.M. High binding capacity of cyclophilin B to chondrocyte heparan sulfate proteoglycans and its release from the cell surface by matrix metalloproteinases: Possible role as a proinflammatory mediator in arthritis. Arthritis Rheum 2003, 48(8):2197-2206.
55. Halestrap A.P., Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 2009, 1787(11):1402-1415.
56. Hausenloy D.J., Ong S.B., Yellon D.M. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009, 104(2):189-202.
57. Morin D., Assaly R., Paradis S., Berdeaux A. Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection. Curr Med Chem 2009, 16(33):4382-4398.
58. Piot C., Croisille P., Staat P., Thibault H., Rioufol G., Mewton N., et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008, 359(5):473-481.
59. Seizer P., Ochmann C., Schonberger T., Zach S., Rose M., Borst O., et al. Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion. Arterioscler Thromb Vasc Biol 2011, 31(6):1377-1386.
60. Gomez L., Thibault H., Gharib A., Dumont J.M., Vuagniaux G., Scalfaro P., et al. Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2007, 293(3):H1654-H1661.
61. Argaud L., Gateau-Roesch O., Muntean D., Chalabreysse L., Loufouat J., Robert D., et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 2005, 38(2):367-374.